EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Dose–response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B

Chi Zhang, Yiqi Liu, Lin Wang, Xueen Liu, Cuiying Chen, Junli Zhang, Chao Zhang, Guiqiang Wang, Hui Zhuang, Hong Zhao, China HepB-Related Fibrosis Assessment Research Group

Hepatology International · 2024

DOI: 10.1007/s12072-024-10709-y ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hepatology International, 2024. Verfasst von Chi Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, 100034, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Liver Cirrhosis, Biomarkers, Polysaccharides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Mega-Project for Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evaluation of liver fibrosis played a monumental role in the diagnosis and monitoring of chronic hepatitis B (CHB). We aimed to explore the value of serum N -glycan markers in liver fibrosis.

Methods

This multi-center (33 hospitals) study recruited 760 treatment-naïve CHB patients who underwent liver biopsy. Serum N -glycan markers were analyzed by DNA sequencer-assisted fluorophore-assisted with capillary electrophoresis (DSA-FACE) technology. First, we explore the relationship between 12 serum N -glycan markers and the fibrosis stage. Then, we developed a Px score for diagnosing significant fibrosis using the LASSO regression. Next, we compared the diagnostic performances between Px, LSM, APRI, and FIB-4. Finally, we explored the relationships between glycosyltransferase gene and liver fibrosis with RNA-transcriptome sequencing.

Results

We included 622 CHB participants: male-dominated (69.6%); median age 42.0 (IQR 34.0–50.0); 287 with normal ALT; 73.0% with significant fibrosis. P5(NA2), P8(NA3), and P10(NA4) were opposite to the degree of fibrosis, while other profiles (except for P0[NGA2]) increased with the degree of fibrosis. Seven profiles (P1[NGA2F], P2[NGA2FB], P3[NG1A2F], P4[NG1A2F], P7[NA2FB], P8[NA3], and P9[NA3Fb]) were selected into Px score. Px score was associated with an increased risk of significant fibrosis (for per Px score increase, the risk of significant fibrosis was increased by 3.54 times (OR = 4.54 [2.63–7.82]) in the fully-adjusted generalized linear model. p for trend was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicLiver CirrhosisBiomarkersPolysaccharidesHumansMaleFemaleAdultMiddle Aged

Stichwörter der Autor:innen

Chronic hepatitis BDiagnostic performanceLiver fibrosisRNA-transcriptome sequencingSerum N-glycan markers

Substanzen

BiomarkersPolysaccharides

Autor:innen und Institutionen

  • Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, 100034, China.
  • Department of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
  • Department of Microbiology & Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
  • Department of Research and Development, Sysdiagno (Nanjing) Biotech Co., Ltd, Nanjing, 210008, Jiangsu Province, China.
  • Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, 100034, China. john31212@126.com.
  • Department of Infectious Diseases, Peking University International Hospital, Beijing, 102206, China. john31212@126.com.

Förderung

  • National Natural Science Foundation of China
  • China Mega-Project for Infectious Diseases

Zitieren

APA

Zhang, C., Liu, Y., Wang, L., Liu, X., Chen, C., Zhang, J., Zhang, C., Wang, G., Zhuang, H., Zhao, H., & China HepB-Related Fibrosis Assessment Research Group (2024). Dose–response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B. Hepatology International. https://doi.org/10.1007/s12072-024-10709-y

Vancouver

Zhang C, Liu Y, Wang L, Liu X, Chen C, Zhang J, et al. Dose–response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B. Hepatology International. 2024. doi:10.1007/s12072-024-10709-y

BibTeX
@article{Zhang2024,
  author = {Zhang, Chi and Liu, Yiqi and Wang, Lin and Liu, Xueen and Chen, Cuiying and Zhang, Junli and Zhang, Chao and Wang, Guiqiang and Zhuang, Hui and Zhao, Hong and China HepB-Related Fibrosis Assessment Research Group, China HepB-Related Fibrosis Assessment Research Group},
  title = {Dose–response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B},
  journal = {Hepatology International},
  year = {2024},
  doi = {10.1007/s12072-024-10709-y}
}
Kostenlos starten →